ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2019, Vol. 28 ›› Issue (2): 166-170.DOI: 10.3969/j.issn.1006-298X.2019.02.015

• 论文 • 上一篇    下一篇

法尼酯X受体:糖尿病肾病防治新靶标

  

  • 出版日期:2019-04-28 发布日期:2019-05-06

Farnesoid X receptor:novel target in  prevention and treatment of diabetic nephropathy

  • Online:2019-04-28 Published:2019-05-06

摘要:

法尼酯X受体(FXR)属于胆汁酸受体,在调节胆汁酸和脂质代谢及维持葡萄糖稳态中发挥重要作用。近来有关FXR的生物学效应及机制在肾脏病的研究取得了新进展,提示FXR的激活对肥胖及糖尿病相关的肾脏损害具有潜在保护作用。本综述主要讨论FXR对糖尿病肾病(DN)血糖、血脂、炎症、氧化应激、蛋白尿和纤维化的影响,以期为DN发病机制提供新的理论依据。

关键词: 法尼酯X受体, 糖尿病肾病

Abstract:

Farnesoid X receptor (FXR),a bile acid receptor,plays pivotal roles in the regulation of bile acid and lipid metabolism and the maintenance of glucose homeostasis.FXR activation potentially protects against obesity or diabetesrelated kidney damage,as suggested by the latest research advances on the biological function of FXR and its signaling pathways in kidney disease.Here,we reviewed how FXR regulates blood glucose,blood lipids,inflammation,oxidative stress,proteinuria and fibrosis in diabetic nephropathy (DN).We expect to provide novel insight into the role of FXR in the pathogenesis of DN.

Key words: farnesoid X receptor, diabetic nephropathy